Earnings summaries and quarterly performance for ASHLAND.
Research analysts who have asked questions during ASHLAND earnings calls.
JE
John Ezekiel Roberts
Mizuho Securities
6 questions for ASH
Also covers: ALB, APD, AXTA +22 more
DB
David Begleiter
Deutsche Bank
5 questions for ASH
Also covers: ALB, APD, AVNT +24 more
Michael Sison
Wells Fargo
5 questions for ASH
Also covers: ALB, APD, AVNT +16 more
Bhavesh Lodaya
BMO Capital Markets
3 questions for ASH
Also covers: DD, DOW, ENTG +4 more
JS
Josh Spector
UBS Group
3 questions for ASH
Also covers: ALB, AMBP, APD +30 more
MH
Michael Harrison
Seaport Research Partners
3 questions for ASH
Also covers: APD, AVNT, AXTA +17 more
CP
Chris Parkinson
Wolfe Research, LLC
2 questions for ASH
Also covers: AXTA, CCK, CTVA +9 more
CP
Christopher Parkinson
Wolfe Research
2 questions for ASH
Also covers: ALB, APD, AXTA +18 more
DR
Daniel Rizzo
Jefferies
2 questions for ASH
Also covers: APD, ATR, AZZ +16 more
EB
Eric Boyce
Evercore
2 questions for ASH
JZ
Jeffrey Zekauskas
JPMorgan Chase & Co.
2 questions for ASH
Also covers: ALB, AMCR, APD +31 more
John McNulty
BMO Capital Markets
2 questions for ASH
Also covers: APD, AVY, AXTA +15 more
Joshua Spector
UBS
2 questions for ASH
Also covers: ALB, AMBP, APD +37 more
MH
Mike Harrison
Seaport Research Partners
2 questions for ASH
Also covers: AVD, AVNT, AXTA +16 more
SH
Steven Haynes
Morgan Stanley
2 questions for ASH
Also covers: ADM, APD, AVNT +3 more
JS
John Spector
UBS
1 question for ASH
Kevin Estok
Jefferies
1 question for ASH
Also covers: AVNT, CBT, CE +8 more
LA
Laurence Alexander
Jefferies
1 question for ASH
Also covers: AIQUY, ALB, APD +27 more
Recent press releases and 8-K filings for ASH.
Ashland's agrimer™ eco-coat polymer seed coating receives EPA approval
ASH
Product Launch
New Projects/Investments
- Ashland's agrimer™ eco-coat polymer seed coating, based on its patented Transformed Vegetable Oils (TVO) technology, has received United States Environmental Protection Agency (EPA) approval.
- This approval allows the ingredient to be used in all food and non-food pesticide formulations under regulation 40 CFR 180.960.
- The EPA posting now enables U.S. growers to buy, sell, and test the agrimer™ eco-coat polymer seed coating, building on previous approvals in Latin America, Europe, and other regions.
- Agrimer™ eco-coat polymer is a nature-based, microplastic-free, and inherently biodegradable advanced seed coating technology.
Feb 9, 2026, 12:00 PM
Ashland Announces Q1 FY26 Financial Results
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland reported Q1 FY26 adjusted sales of $386 million, a 5% decrease year-over-year, with adjusted EBITDA also down 5% to $58 million and adjusted EPS at $0.26, a 7% decline compared to the prior-year quarter.
- Segment performance was mixed, with Life Sciences sales growing 4% year-over-year, while Personal Care sales decreased 8% (or 1% organically excluding the Avoca divestiture), Specialty Additives sales fell 11%, and Intermediates sales were down 6%.
- The company generated $26 million in ongoing Free Cash Flow in Q1 FY26, a significant improvement from a negative $26 million in Q1 FY25.
- Ashland reaffirmed its FY26 outlook, projecting sales between $1,835 million and $1,905 million and adjusted EBITDA between $400 million and $420 million, with double-digit-plus adjusted EPS growth.
Feb 3, 2026, 2:00 PM
Ashland Reports Q1 2026 Financial Results and Updates Fiscal 2026 Outlook
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland reported Q1 2026 sales of $386 million, a 5% decrease year-over-year, and adjusted EBITDA of $58 million, also down 5% year-over-year, with adjusted EPS at $0.26. The quarter's adjusted EBITDA included a $10 million impact from the Calvert City outage, which led to over 250 basis points of margin compression.
- The company narrowed its fiscal 2026 adjusted EBITDA guidance to $400 million-$420 million, reflecting an anticipated $11 million impact in Q2 from the extended Calvert City startup delay and recent weather-related disruptions.
- While Life Sciences delivered healthy growth and Personal Care remained stable, Specialty Additives experienced muted demand in coatings and construction, particularly in China and export markets.
- Ashland is on track with its cost savings target of $30 million for fiscal 2026 and expects to deliver $35 million in revenue from its Globalize and Innovate platforms, which are showing strong momentum.
- The company identifies GLP-1 formulations and oral biologics as a significant opportunity for its VP&D portfolio and tablet coatings, with multiple active projects and new innovations like sodium caprate.
Feb 3, 2026, 2:00 PM
Ashland Reports Q1 2026 Results, Narrows Fiscal 2026 Adjusted EBITDA Guidance
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland reported Q1 2026 sales of $386 million, a 5% decrease year-over-year (or 3% excluding the Avoca divestiture), and adjusted EBITDA of $58 million, also down 5% year-over-year (or 3% excluding the divestiture).
- Adjusted EPS, excluding intangible amortization, was $0.26, a 7% decrease from the prior year.
- The company generated $125 million of cash from operating activities and $26 million of ongoing free cash flow in Q1 2026.
- Operational challenges, including the Calvert City outage and recent weather-related disruptions, are expected to result in approximately $11 million of temporary impacts in Q2 2026, extending the impact from Q1.
- Ashland is on track to deliver its fiscal 2026 targets for $35 million in revenue from Globalize and Innovate platforms and $30 million in total cost savings, and has narrowed its fiscal 2026 adjusted EBITDA guidance range to $400 million-$420 million.
Feb 3, 2026, 2:00 PM
Ashland Inc. Reports Q1 2026 Results and Updates Fiscal 2026 Outlook
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland Inc. reported Q1 2026 sales of $386 million, a 5% decrease year-over-year, and adjusted EBITDA of $58 million, also down 5%.
- The company narrowed its fiscal 2026 adjusted EBITDA outlook to $400 million-$420 million, while other guidance elements remain unchanged.
- Operational challenges, including a $10 million adjusted EBITDA impact from the Calvert City outage in Q1, are now expected to extend into Q2 2026.
- Life Sciences sales increased 4% to $139 million, with adjusted EBITDA growing 11% to $31 million, driven by strong pharma demand and innovation.
- Ashland is on track to achieve its fiscal 2026 $35 million revenue commitment from Globalize and Innovate initiatives, having generated $3 million and $6 million in incremental sales respectively in Q1 2026.
Feb 3, 2026, 2:00 PM
Ashland Inc. Reports Q1 Fiscal 2026 Results and Narrows Full-Year Outlook
ASH
Earnings
Guidance Update
- Ashland Inc. reported Q1 fiscal 2026 sales of $386 million, a five percent decrease from the prior-year quarter, and a net loss of $12 million, or $(0.26) per diluted share.
- Adjusted EBITDA for Q1 fiscal 2026 was $58 million, representing a 15 percent margin, which is down five percent from the prior-year quarter.
- The company narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to a range of $400 million to $420 million from its prior guidance of $400 million to $430 million. This adjustment reflects approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions, isolated to the second quarter.
- All other elements of the full-year guidance remain unchanged, including sales guidance of $1,835 million to $1,905 million.
Feb 2, 2026, 10:11 PM
Ashland Reports Q1 FY2026 Results and Narrows Full-Year Outlook
ASH
Earnings
Guidance Update
Demand Weakening
- For the first quarter of fiscal year 2026, which ended December 31, 2025, Ashland reported sales of $386 million, a five percent decrease from the prior-year quarter.
- The company recorded a net loss of $12 million, or $(0.26) per diluted share, and Adjusted EBITDA of $58 million for the quarter.
- Ashland narrowed its full-year fiscal 2026 Adjusted EBITDA guidance to $400–$420 million, reflecting approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions isolated to the second quarter.
- Cash flows provided by operating activities were $125 million, and Ongoing Free Cash Flow totaled $26 million for the quarter.
Feb 2, 2026, 10:01 PM
Ashland Reports Q4 2025 Results and Provides Fiscal 2026 Guidance
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland reported Q4 2025 sales of $478 million, an 8% year-over-year decrease primarily due to portfolio optimization, and adjusted EBITDA of $119 million, down 4% year-over-year. On a comparable basis (excluding portfolio actions), sales declined 1% and adjusted EBITDA increased 5%, with margins expanding to 24.9%.
- Life Sciences and Personal Care segments demonstrated resilience, while Specialty Additives and Intermediates faced continued pressure from market conditions and competitive intensity.
- The company completed its $30 million restructuring program, realizing $20 million in savings in fiscal 2025, and expects an additional $12 million in fiscal 2026. The manufacturing optimization initiative is also progressing, with $5 million in savings in fiscal 2025 and $18 million projected for fiscal 2026.
- For fiscal 2026, Ashland projects full-year sales between $1,835 million and $1,905 million (1%-5% organic growth) and adjusted EBITDA between $400 million and $430 million. Adjusted EPS is expected to grow double digits plus, and free cash flow conversion is targeted at 50%.
Nov 5, 2025, 3:00 PM
Ashland Reports Q4 2025 Financial Results and Provides FY26 Outlook
ASH
Earnings
Guidance Update
Demand Weakening
- For Q4 FY25, Ashland reported sales of $478 million, an 8% decrease from Q4 FY24, and Adjusted EBITDA of $119 million, a 4% decrease.
- The company achieved an Adjusted EBITDA margin of 24.9% in Q4 FY25, an increase of 110 basis points compared to the prior-year quarter, driven by cost savings and mix.
- Adjusted EPS for Q4 FY25 was $1.08, down 14% from Q4 FY24, and ongoing Free Cash Flow was $52 million, a 41% decrease.
- For fiscal year 2026, Ashland anticipates sales between $1,835 million and $1,905 million and Adjusted EBITDA between $400 million and $430 million.
- The company expects double-digit-plus Adjusted EPS growth and approximately 50% ongoing Free Cash Flow conversion of Adjusted EBITDA in FY26.
Nov 5, 2025, 3:00 PM
Ashland Inc. Reports Q4 2025 Results and Issues FY 2026 Outlook
ASH
Earnings
Guidance Update
Demand Weakening
- Ashland Inc. reported fourth-quarter fiscal year 2025 sales of $478 million, an eight percent decrease from the prior-year quarter, and net income of $32 million, or $0.71 per diluted share.
- Adjusted EBITDA for Q4 2025 was $119 million, down four percent from the prior-year quarter, with cash flows provided by operating activities at $40 million and Ongoing Free Cash Flow of $52 million.
- For the full fiscal year 2025, sales were $1.824 billion, a 14 percent decrease year-over-year, resulting in a net loss of $845 million, or ($18.23) per diluted share, and Adjusted EBITDA of $401 million.
- Ashland issued full-year fiscal 2026 guidance, projecting sales between $1,835 million and $1,905 million, and Adjusted EBITDA between $400 million and $430 million.
Nov 4, 2025, 10:07 PM
Quarterly earnings call transcripts for ASHLAND.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more